306 related articles for article (PubMed ID: 16304146)
1. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
2. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
3. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
4. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
[TBL] [Abstract][Full Text] [Related]
5. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
6. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Gilbert C; Azzi A; Goyette N; Lin SX; Boivin G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4019-27. PubMed ID: 21709106
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
8. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
9. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Baldanti F; Lilleri D; Campanini G; Comolli G; Ridolfo AL; Rusconi S; Gerna G
J Antimicrob Chemother; 2004 Mar; 53(3):536-9. PubMed ID: 14739146
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
13. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
[TBL] [Abstract][Full Text] [Related]
15. Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Pérez JL
Microbiologia; 1997 Sep; 13(3):343-52. PubMed ID: 9353754
[TBL] [Abstract][Full Text] [Related]
16. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
18. Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Chou S; Ercolani RJ; Lanier ER
Antimicrob Agents Chemother; 2016 Jun; 60(6):3845-8. PubMed ID: 27044553
[TBL] [Abstract][Full Text] [Related]
19. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
[TBL] [Abstract][Full Text] [Related]
20. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]